转移因子用于II期恶性黑色素瘤的随机对照试验。

Randomized controlled trial of transfer factor in Stage II malignant melanoma.

作者信息

Bukowski R M, Deodhar S, Hewlett J S, Greenstreet R

出版信息

Cancer. 1983 Jan 15;51(2):269-72. doi: 10.1002/1097-0142(19830115)51:2<269::aid-cncr2820510217>3.0.co;2-6.

DOI:10.1002/1097-0142(19830115)51:2<269::aid-cncr2820510217>3.0.co;2-6

Abstract

Thirty-six patients with Stage II malignant melanoma were randomized to no further therapy or transfer factor (TF) following surgical removal of all evident disease. Eighteen patients received TF, and 18 were in the surgery only group. Median disease-free intervals were 12.0 and 10.0 months, and survival, 40.8 and 27.0 months, respectively. Nine TF patients and four control patients remain alive. These differences were not statistically significant, and no adjuvant effect of TF could be demonstrated.

摘要

36例II期恶性黑色素瘤患者在手术切除所有明显病灶后，被随机分为不再接受进一步治疗组或转移因子（TF）组。18例患者接受TF治疗，18例仅接受手术治疗。无病生存期的中位数分别为12.0个月和10.0个月，生存期分别为40.8个月和27.0个月。9例接受TF治疗的患者和4例对照组患者仍存活。这些差异无统计学意义，且未显示TF有辅助治疗作用。